The stock of Entero Therapeutics Inc. (ENTO) has gone up by 74.48% for the week, with a 48.33% rise in the past month and a -42.34% drop in the past quarter. The volatility ratio for the week is 27.74%, and the volatility levels for the past 30 days are 17.93% for ENTO. The simple moving average for the last 20 days is 70.39% for ENTO stock, with a simple moving average of -78.84% for the last 200 days.
Is It Worth Investing in Entero Therapeutics Inc. (NASDAQ: ENTO) Right Now?
Company’s 36-month beta value is 1.33.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ENTO is 3.16M, and currently, short sellers hold a 4.03% ratio of that floaft. The average trading volume of ENTO on October 07, 2024 was 561.07K shares.
ENTO) stock’s latest price update
Entero Therapeutics Inc. (NASDAQ: ENTO)’s stock price has increased by 72.12 compared to its previous closing price of 0.35. However, the company has seen a 74.48% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-23 that BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) — Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that, because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). Nasdaq has informed the Company that it has until October 21, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq approves the Company’s plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the Form 10-Q (or until February 17, 2025) to regain compliance.
ENTO Trading at 41.71% from the 50-Day Moving Average
After a stumble in the market that brought ENTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.87% of loss for the given period.
Volatility was left at 17.93%, however, over the last 30 days, the volatility rate increased by 27.74%, as shares surge +51.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.68% lower at present.
During the last 5 trading sessions, ENTO rose by +74.48%, which changed the moving average for the period of 200-days by -82.57% in comparison to the 20-day moving average, which settled at $0.3622. In addition, Entero Therapeutics Inc. saw -85.72% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTO starting from Romano Sarah, who sale 621 shares at the price of $1.07 back on Jul 02 ’24. After this action, Romano Sarah now owns 18,490 shares of Entero Therapeutics Inc., valued at $664 using the latest closing price.
SAPIRSTEIN JAMES, the Chairman and CEO of Entero Therapeutics Inc., sale 1,289 shares at $1.07 during a trade that took place back on Jul 02 ’24, which means that SAPIRSTEIN JAMES is holding 35,816 shares at $1,379 based on the most recent closing price.
Stock Fundamentals for ENTO
The total capital return value is set at -0.25. Equity return is now at value -15.28, with -12.74 for asset returns.
Based on Entero Therapeutics Inc. (ENTO), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -1.9. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -262.73.
Currently, EBITDA for the company is -15.74 million with net debt to EBITDA at -0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.21.
Conclusion
In a nutshell, Entero Therapeutics Inc. (ENTO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
